Quantitative Evaluation of Antibiotic Utilization Using the ATC/DDD and DU90% Methods and Length of Hospital Stay Among Pediatric and Adult Pneumonia Patients in Bima
DOI:
https://doi.org/10.15408/pbsj.v7i2.49345Abstract
The primary treatment modality for pneumonia is antibiotic therapy, yet improper use can accelerate bacterial resistance and diminish therapeutic effectiveness. The study aims to evaluate the patterns of antibiotic utilization among hospitalized pediatric and adult patients with pneumonia in a hospital in Bima City, as well as to examine the factors influencing the length of hospital stay during the period of January to August 2020. The evaluation employed the WHO ATC/DDD methodology combined with DU 90% analysis using a descriptive cross-sectional design. Data were obtained retrospectively from medical records, and total sampling. A total of 95 patients met the inclusion criteria, representing all age categories with complete and legible documentation. Quantitative analysis showed that the total antibiotic consumption in pediatric patients reached 39.27 DDD per 100 patient-days, while in adult patients it reached 121.26 DDD per 100 patient-days. Ceftriaxone was the antibiotic with the highest DDD value in pediatric patients and adult patients, with 19.53 and 98.00 DDD/100 patient-days respectively. In the pediatric group, antibiotics within the DU 90 percent segment comprised ceftriaxone, gentamicin, cefotaxime, and azithromycin, whereas in adults, the DU 90 percent segment included ceftriaxone and azithromycin. A total of 97.6 percent of prescriptions were aligned with the hospital formulary. The bivariate analysis indicates that the presence of comorbidities is significantly associated with the length of hospital stay among pneumonia patients (p < 0.05). Meanwhile, patient age and nutritional status did not show a significant association (p > 0.05). Overall, the findings demonstrate a predominance of ceftriaxone use in the management of pneumonia in the hospital. These results highlight the importance of ongoing quantitative surveillance to monitor prescribing trends, and support implementation of antimicrobial stewardship programs to minimize resistance risk and maintain optimal therapeutic outcomes.
Keywords: Antibiotic use; Antimicrobial Stewardship Program; ATC/DDD; Ceftriaxone; DU 90%; Pneumonia
References
Amrina, D., Putri, A., Safitri, N., 2025. Analisis efektivitas biaya terapi antibiotik pada pneumonia di RSUD Sleman tahun 2023. Jurnal Farmasi dan Sains Indonesia 8(1).
Aryani, F., Sutanto, A., Widodo, D., 2017. Evaluasi penggunaan antibiotik pada pasien pneumonia rawat inap di RSUD Dr. Soetomo. Jurnal Farmasi Klinik Indonesia 6, 159–167.
Dadgostar, P., 2019. Antimicrobial resistance: implications and costs. Infection and Drug Resistance 12, 3903–3910. https://doi.org/10.2147/IDR.S234610
Dewi Lokida, H., Farida, H., Triasih, R., Mardian, Y., et al., 2022. Epidemiology of community-acquired pneumonia among hospitalized children in Indonesia: a multicenter, prospective study. BMJ Open.
European Respiratory Society, European Society of Intensive Care Medicine, European Society of Clinical Microbiology and Infectious Diseases, Latin American Thoracic Association, 2023. Guidelines for the management of severe community-acquired pneumonia. European Respiratory Journal 61, 2200735.
Farida, H., Rasyid, A., Nurdin, R., Lestari, E., 2020. Inappropriate antibiotic use in Indonesia: a systematic review. Int. J. Pharm. Pharm. Sci. 12, 40–45.
Farida, H., Trisna, E., Nur, R., 2017. Pola penggunaan antibiotik pada pasien pneumonia di Rumah Sakit Rujukan Daerah Surakarta. Jurnal Ilmu Farmasi dan Farmasi Klinik Indonesia 14, 87–94.
Kartasasmita, C.B., et al., 2022. Epidemiology of community-acquired pneumonia among hospitalised children in Indonesia: a multicentre, prospective study. BMJ Open 12, e055054.
Kementerian Kesehatan Republik Indonesia, 2016. Peraturan Menteri Kesehatan Nomor 2406 Tahun 2016 tentang Pedoman Penggunaan Antibiotik. Jakarta.
Kementerian Kesehatan Republik Indonesia, 2020. Profil Kesehatan Indonesia 2020. Jakarta.
Kementerian Kesehatan Republik Indonesia, 2023. Survei Kesehatan Indonesia (SKI) 2023: Hasil Utama. Badan Kebijakan Pembangunan Kesehatan, Jakarta.
Kulkarni, D., et al., 2016. Drug utilization 90%: an innovative method in assessing drug prescribing pattern. Int. J. Basic Clin. Pharmacol.
Martin-Loeches, I., et al., 2023. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Medicine 49, 615–632.
Masdin, M.R., Sari, D., Wijaya, R., 2025. Pola penggunaan antibiotik pada pasien anak dengan community-acquired pneumonia di ruang rawat inap RSUP Kabupaten Kolaka Timur. Jurnal Pharma Saintika 9, 107–114.
Masalma, R., Abaza, A., Khalil, R., et al., 2024. Antibiotic utilization in orthopedic surgical wards: an ATC/DDD-based analysis. BMC Infectious Diseases 24, 1–9.
Mathew, M., et al., 2024. Cephalosporins in pediatrics: navigating antimicrobial resistance impact and adverse effects – a comprehensive review. Indian J. Clin. Exp. Dermatol. 10, 122–128.
Metlay, J.P., 2019. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline. Am. J. Respir. Crit. Care Med. 200, e45–e67.
Nasution, E.S., et al., 2023. DDD and DU 90% methods on ICU patients. Pharmacia.
Nunes, P.H.C., et al., 2022. Antibiotic consumption and deviation of prescribed daily dose in primary health care. Int. J. Environ. Res. Public Health.
Prasetyo, A., Kusumaratni, M., 2018. Evaluasi penggunaan antibiotik pneumonia rawat inap di RS DKT Kediri. Indones. J. Clin. Pharm. 7, 87–94.
Putri, S.A., et al., 2024. Pneumonia among children in Greater Jakarta: incidence and epidemiology from 2020 to 2022. Front. Pediatr. 12, 1361937.
Qalehsari, M.Q., Heydari, A., Khorasani-Zavareh, D., 2017. The effect of comorbidity on length of hospital stay in patients with pneumonia. J. Clin. Diagn. Res. 11, OC01–OC04.
Same, R.G., et al., 2020. The association of antibiotic duration with successful treatment of community-acquired pneumonia in children. J. Pediatr. Infect. Dis. Soc. 10, 267–273.
Tejada, S., Romero, R., Rello, J., 2018. Community-acquired pneumonia in developing countries: the burden and risk factors. Respiratory Medicine 136, 42–49.
UNICEF, 2023. Pneumonia data and statistics. New York.
Windi, R., Efendi, F., Qona’ah, A., 2021. Determinants of acute respiratory infection among children under five years in Indonesia. J. Pediatr. Nurs. 60.
World Health Organization, 2014. Revised WHO classification and treatment of pneumonia in children at health facilities. Geneva.
World Health Organization, 2018. WHO Model List of Essential Medicines: 20th List (including AWaRe classification). Geneva.
World Health Organization, 2019. Pneumonia in children: global health estimates. Geneva.
World Health Organization, 2022. Pneumonia in children. Geneva.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Jihan Istiqomah, Azrifitria , MSi, Marvel
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
